



## International Vet Cancer Specialist Joins PharmAust Veterinary Advisory Board

**18 December 2017 – Perth, Australia:** PharmAust (ASX:PAA), a clinical-stage oncology company, has appointed eminent US-based veterinary cancer specialist Dr Barbara Kitchell to its Veterinary Advisory Board.

Dr Kitchell is Director of Residency Training for Veterinary Centers of America and staff oncologist at the VCA Veterinary Care Animal Hospital and Referral Center in New Mexico. Previously, she was Professor and Director of the Center for Comparative Oncology at Michigan State University. She has also held academic and clinical positions specialising in comparative oncology at other prestigious institutions including Stanford University, University of Illinois and University of California, Davis.

Dr Kitchell is recognised as a key opinion leader in comparative oncology, clinical trials and drug development.

Dr Kitchell has successfully led more than 27 clinical studies and is a member of various national and international veterinary cancer organisations. She is the author of over 100 scientific publications, abstracts, proceedings, book chapters and handbooks in her field of veterinary and comparative oncology.

Dr Kitchell commented "*As a comparative oncologist I am very pleased to join the PharmAust advisory board to support the development of drugs that will potentially help both animals and humans.*"

Dr Frimberger, the Chair of PharmAust's Vet Advisory Committee said "*Dr Kitchell brings a wealth of expertise in general veterinary oncology and new drug development and shares our interest in mTOR inhibitors. With everything that she brings to this team, I can't wait to get to work!*"

PharmAust's CEO Dr Richard Hopkins said "*We are delighted to have attracted another world leader in the field of comparative oncology to our highly credentialed advisory team. Dr Kitchell's expertise and networks will be invaluable as we look to accelerate clinical development of our lead candidate in Australia and overseas.*"

**Enquiries:**

**Dr Richard  
CEO**  
Tel: 0405 656 868  
[rhopkins@pharmaust.com](mailto:rhopkins@pharmaust.com)

**Hopkins**

**Dr Roger Aston  
Executive Chairman**  
Tel: 0402 762 204  
[raston@pharmaust.com](mailto:raston@pharmaust.com)

**About PharmAust (PAA):**

PAA is a clinical-stage company developing targeted cancer therapeutics for both humans and animals. The company specialises in repurposing marketed drugs lowering the risks and costs of development. These efforts are supported by PAA's subsidiary, Epichem, a highly successful contract medicinal chemistry company which generated \$3.05m in revenues in the 2017FY.

PAA's lead drug candidate is monepantel (MPL), a novel, potent and safe inhibitor of the mTOR pathway - a key driver of cancer. MPL has been evaluated in Phase 1 clinical trials in humans and dogs. MPL treatment was well-tolerated and produced a significant reduction in key prognostic biomarkers. PAA is uniquely positioned to commercialise MPL for treatment of human and veterinary cancers as it advances the drug into Phase 2 clinical trial.